Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.
Company Growth (employees)
Newton, US
Size (employees)
105 (est)
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US

Key People at Karyopharm Therapeutics

Michael Kauffman

Michael Kauffman

Chief Executive Officer &Board of Directors
John McCartney

John McCartney

Senior Director, Product Leadership
Brian Austad

Brian Austad

Vice President, Head of Pharmaceutical Sciences
Dilara McCauley

Dilara McCauley

Vice President, Product Leadership

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton and München
Newton, US (HQ)
85 Wells Ave
München, DE
9 Franziska Bilek Weg

Karyopharm Therapeutics Data and Metrics

Karyopharm Therapeutics Financial Metrics

Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

250 k

Revenue growth (FY, 2014 - FY, 2015), %


Net income (FY, 2015)

(118.2 m)

EBIT (FY, 2015)

(119.1 m)

Market capitalization (22-Jun-2017)

469.3 m

Closing share price (22-Jun-2017)


Cash (31-Dec-2016)

49.7 m
Karyopharm Therapeutics's current market capitalization is $469.3 m.
FY, 2013FY, 2014FY, 2015


387 k229 k250 k

Revenue growth, %


R&D expense

28.5 m60.1 m97.7 m

General and administrative expense

5.9 m15.9 m21.6 m

Operating expense total

34.3 m76.1 m119.3 m


(34 m)(75.8 m)(119.1 m)

EBIT margin, %


Interest expense

1 k

Interest income

3 k97 k897 k

Net Income

(33.9 m)(75.8 m)(118.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016


156 m150.6 m58.4 m49.7 m


2 m2 m2 m2.1 m

Current Assets

158 m207.8 m177.6 m131.6 m


240 k2.8 m3.5 m2.8 m

Total Assets

158.2 m220.3 m215.4 m180.4 m

Accounts Payable

1.7 m6.3 m3.8 m4.8 m

Current Liabilities

3.3 m12.3 m15.1 m16.5 m

Additional Paid-in Capital

217.5 m345.2 m455.2 m528.6 m

Retained Earnings

(138.3 m)(256.5 m)(366.1 m)

Total Equity

154.9 m206.8 m198.4 m162.2 m

Financial Leverage

1 x1.1 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)

Depreciation and Amortization

144 k323 k634 k717 k


(1.4 m)(45 k)(55 k)(120 k)

Accounts Payable

664 k4.5 m(2.4 m)945 k

Cash From Operating Activities

(30.3 m)(51.4 m)(94 m)(84.4 m)

Purchases of PP&E

(57 k)(2.8 m)(1.4 m)(70 k)

Cash From Investing Activities

(57 k)(67 m)(90.8 m)24.6 m

Cash From Financing Activities

185.9 m113.1 m92.7 m51.2 m
Y, 2016

Financial Leverage

1.1 x

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Granted


Karyopharm Therapeutics Market Value History

Karyopharm Therapeutics Online and Social Media Presence

Karyopharm Therapeutics News and Updates

Karyopharm Therapeutics Company Life and Culture

You may also be interested in